Overall Risk Summary
The main risk is not that the chemistry fails in the lab; it is that Amprius cannot convert differentiated cells into repeat, qualified, partner-made volume quickly enough. Supplier concentration, manufacturing transfer risk, and a rich starting valuation mean even good execution must be timely and clean.